Operational Costs Compared: SG&A Analysis of argenx SE and CRISPR Therapeutics AG

SG&A Expenses: Argenx SE vs. CRISPR Therapeutics AG

__timestamp	CRISPR Therapeutics AG	argenx SE
Wednesday, January 1, 2014	5114000	4241601.57
Thursday, January 1, 2015	13403000	5392385.38
Friday, January 1, 2016	31056000	7370036.73
Sunday, January 1, 2017	35845000	14970357
Monday, January 1, 2018	48294000	31413266
Tuesday, January 1, 2019	63488000	72279461
Wednesday, January 1, 2020	88208000	183907682
Friday, January 1, 2021	102802000	307644000
Saturday, January 1, 2022	102464000	472132000
Sunday, January 1, 2023	76162000	709539000
Monday, January 1, 2024	72977000

Unveiling the hidden dimensions of data

A Decade of SG&A Evolution: Argenx SE vs. CRISPR Therapeutics AG

In the dynamic world of biotechnology, operational costs are a critical factor in determining a company's financial health. Over the past decade, from 2014 to 2023, the Selling, General, and Administrative (SG&A) expenses of Argenx SE and CRISPR Therapeutics AG have shown significant trends. Argenx SE's SG&A expenses have skyrocketed by over 16,000%, peaking in 2023, reflecting its aggressive expansion and operational scaling. In contrast, CRISPR Therapeutics AG experienced a more moderate increase of approximately 1,400%, with a notable peak in 2021. This divergence highlights Argenx SE's rapid growth strategy compared to CRISPR's more measured approach. As the biotech industry continues to evolve, understanding these financial dynamics offers valuable insights into each company's strategic priorities and market positioning.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025